Study Details

Back to Search Results

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01197885

Astellas Study ID

The unique identification code given by the study sponsor.

GM-IMAB-001-02

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2009-017365-36

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 Years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2010 - Aug 2015

Masking

None (Open Label)

Enrollment number

54

International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Universitätsklinikum Essen, Innere Klinik (Tumorforschung)

Essen, Germany, 45122

Piejuras Hospital

Liepaja, Latvia

Paula Stradina Clinical University Hospital

Riga, Latvia, 1002

Krankenhaus Nordwest, Klinik für Onkologie und Hämatologie

Frankfurt, Germany, 60488

Universitätsklinikum Heidelberg, NCT

Heidelberg, Germany, 69120

Medizinische Universität Wien

Wien, Austria, 1090

Universitätsmedizin der Johannes-Gutenberg Universität

Mainz, Germany, 55101

Vilnius University

Vilnius, Lithuania, 08660

Kantonsspital St. Gallen

St.Gallen, Switzerland, 9007

Klinikum Braunschweig

Braunschweig, Germany, 38114

Universitätsklinikum Halle

Halle, Germany, 06120

Universitätsklinikum Leipzig

Leipzig, Germany, 04103

Medizinische Univeritätsklinik Ruhr-Universität Bochum

Bochum, Germany, 44892

Riga East Clinical Research

Riga, Latvia, 1038

Klinikum rechts der Isar

Muenchen, Germany, 81675

Charité - Universitätsmedizin Berlin

Berlin, Germany, 13353

Oncology Dispensary "Dr. Marko Markov"

Varna, Bulgaria, 9002

MHAT "St.Marina"

Varna, Bulgaria, 9010

Complex Oncology Center

Veliko Turnovo, Bulgaria, 5000

Universitäres Cancer Center Universitätsklinikum Eppendorf

Hamburg, Germany, 20246

Onkologische Schwerpunktpraxis Eppendorf

Hamburg, Germany, 20249

Universitätsklinikum Ulm

Ulm, Germany, 89081

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo